Noxopharm Limited (ASX:NOX) today has released details of the radiographic review of its DARRT-1 clinical study.
What are the key highlights?
- The review shows a major benefit from a combination of the company's Veyonda® and low-dose radiotherapy.
- The rationale behind DARRT is the use of a low dose of radiation to trigger an immune response to the cancer in one particular tumour, with Veyonda® then promoting a generalised spread of that immune response to tumours elsewhere in the body.
- An anti-cancer response in distant non-irradiated lesions is known as an ‘abscopal response’ and has become a major new direction in oncology, offering the ability to achieve a significant anti-cancer effect with low, well-tolerated doses of radiation.
- Noxopharm is developing the DARRT treatment regimen as a means of converting palliative therapy(mainly radiotherapy) into a therapy delivering a meaningful therapeutic outcome in patients with end-stage cancer. The Company is starting with end-stage prostate cancer.
For further details, please see the announcement linked below.